Verastem, Inc. (VSTM)
| Market Cap | 380.49M -2.9% |
| Revenue (ttm) | 49.59M +395.9% |
| Net Income | -193.96M |
| EPS | -2.41 |
| Shares Out | 87.87M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,106,013 |
| Open | 4.280 |
| Previous Close | 4.290 |
| Day's Range | 4.220 - 4.405 |
| 52-Week Range | 4.000 - 11.245 |
| Beta | 0.34 |
| Analysts | Strong Buy |
| Price Target | 16.00 (+269.52%) |
| Earnings Date | May 7, 2026 |
About VSTM
Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, which is an orally administered, small molecule dual RAF/MEK inhibitor developed to block MEK kinase activity and the compensatory reactivation of MEK by upstream RAF, thereby targeting the RAS/MAPK signaling pathway that is commonly activated in various cancers; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine ki... [Read more]
Financial Performance
In 2025, Verastem's revenue was $30.91 million, an increase of 209.14% compared to the previous year's $10.00 million. Losses were -$209.47 million, 60.3% more than in 2024.
Financial StatementsAnalyst Summary
According to 9 analysts, the average rating for VSTM stock is "Strong Buy." The 12-month stock price target is $16.0, which is an increase of 269.52% from the latest price.
News
Verastem Oncology to Present at Jefferies Healthcare Conference
BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that its ...
Verastem appoints Michael Bailey to board of directors
Verastem (VSTM) Oncology announced the appointment of Michael Bailey to its Board of Directors. The Company also announced that Robert Gagnon stepped down from the Board following the end of…
Verastem Oncology Appoints Michael P. Bailey to its Board of Directors
BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced the appoi...
Verastem Transcript: RBC Capital Markets Global Healthcare Conference 2026
VS-7375 is advancing in the U.S. with promising safety and efficacy, leveraging learnings from Chinese trials and higher dosing. Regulatory strategy includes separate phase II protocols and phase III plans, while commercial efforts for Avmapki Fakzynja focus on education, analytics, and expanding patient access.
Verastem Transcript: H.C. Wainwright 4th Annual BioConnect Investor Conference
Focused on RAS/MAPK cancers, the company has achieved accelerated approval for its LGSOC therapy and is advancing a KRAS G12D inhibitor with strong early results. Phase II trials in multiple cancers begin in June, with label expansion and pivotal data readouts expected next year.
Verastem price target lowered to $14 from $16 at Mizuho
Mizuho analyst Graig Suvannavejh lowered the firm’s price target on Verastem (VSTM) to $14 from $16 and keeps an Outperform rating on the shares. The firm updated the company’s model…
Verastem Oncology to Present at Upcoming Investor Conferences
BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that its ...
Verastem Q1 Earnings Call Highlights
Verastem NASDAQ: VSTM reported first-quarter 2026 net product revenue of $18.7 million for AVMAPKI FAKZYNJA CO-PACK, as management said the launch of the therapy for KRAS-mutated recurrent low-grade s...
Verastem price target lowered to $18 from $19 at BTIG
BTIG lowered the firm’s price target on Verastem (VSTM) to $18 from $19 and keeps a Buy rating on the shares after its Q1 results. The revamped commercial efforts should…
On World Ovarian Cancer Day, LGSOC Resource Guide Launches to Support People Living with Low-Grade Serous Ovarian Cancer
BOSTON--(BUSINESS WIRE)--Today, STAAR Low-Grade Serous Ovarian Cancer Foundation, Not These Ovaries, and Verastem Oncology announced the launch of the LGSOC Resource Guide, a unique resource designed ...
Verastem price target raised to $18 from $16 at Alliance Global
Alliance Global raised the firm’s price target on Verastem (VSTM) to $18 from $16 and keeps a Buy rating on the shares after the company’s Q1 earnings report included detailing…
Verastem reports Q1 adjusted EPS (43c), consensus (47c)
Reports Q1 revenue $18.67M, consensus $21.39M. “As we mark the one-year anniversary of the FDA-approval of AVMAPKI FAKZYNJA CO-PACK for KRAS-mutated recurrent low-grade serous ovarian cancer, I am inc...
Verastem Earnings Call Transcript: Q1 2026
Q1 2026 saw $18.7M in net product revenue and expanding prescriber adoption, with the LGSOC franchise expected to be self-sustaining in H2 2026. R&D advanced with new phase II trials for VS-7375, and cash runway extends into H1 2027.
Verastem Earnings release: Q1 2026
Verastem released its Q1 2026 earnings on May 7, 2026, summarizing the period's financial results.
Verastem Quarterly report: Q1 2026
Verastem has published its Q1 2026 quarterly earnings report on May 7, 2026.
Verastem Slides: Q1 2026
Verastem has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 7, 2026.
Verastem Oncology Reports First Quarter 2026 Financial Results and Highlights Recent Business Updates
BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today reported financial ...
Verastem announces launch of Reimagine Recurrent LGSOC campaign
Verastem (VSTM) Oncology announced the launch of its Reimagine Recurrent Low-Grade Serous Ovarian Cancer, LGSOC, campaign for Avmapki Fakzynja Co-Pack, the first and only treatment specifically approv...
Verastem Oncology Launches HCP and Patient Reimagine Campaign to Increase Awareness of AVMAPKI® FAKZYNJA® CO-PACK for KRAS-Mutated Recurrent Low-Grade Serous Ovarian Cancer
BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced the launc...
Verastem Oncology to Report First Quarter 2026 Financial Results on May 7, 2026
BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that the ...
Verastem announces two-year median follow-up data on AVMAPKI FAKZYNJA combo
Verastem (VSTM) Oncology announced two-year median follow-up data from the Phase 2 RAMP 201 clinical trial that evaluated AVMAPKI FAKZYNJA combination therapy in patients with recurrent low-grade sero...
Verastem Oncology Announces Two-Year Median Follow-Up Data on AVMAPKI® FAKZYNJA® Combination Therapy (avutometinib capsules; defactinib tablets) in Recurrent Low-Grade Serous Ovarian Cancer at the SGO 2026 Annual Meeting on Women's Cancers
BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced two-year ...
Verastem Proxy statement: Proxy filing
Verastem filed a proxy statement on April 9, 2026, providing details for shareholder voting and corporate governance matters.
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced the grant...
Verastem assumed with a Buy at Jefferies
Jefferies analyst Faisal Khurshid assumed coverage of Verastem (VSTM) with a Buy rating and a price target of $15, down from $19. The firm sees “a two-pillar story” with drug…